These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 6858169

  • 1. [Pharmacokinetics and acute signs of cardiac toxicity during doxorubicin therapy].
    Lenzhofer R, Schneeweiss B, Rameis H, Eichler H, Graninger W, Dittrich C, Dudczak R, Ganzinger U, Gasic S, Moser K.
    Wien Klin Wochenschr; 1983 Jan 21; 95(2):52-5. PubMed ID: 6858169
    [Abstract] [Full Text] [Related]

  • 2. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S, Tucci A, Villani G, Carteni G, Spadini N, Palumbo R.
    Anticancer Res; 2000 Jan 21; 20(1B):485-91. PubMed ID: 10769710
    [Abstract] [Full Text] [Related]

  • 3. 1-year followup of cardiac status after adriamycin therapy.
    Friedman MJ, Ewy GA, Jones SE, Cruze D, Moon TE.
    Cancer Treat Rep; 1979 Jan 21; 63(11-12):1809-16. PubMed ID: 526915
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Noninvasive polygraphic cardiac changes in daunorubicin-induced cardiomyopathy in rabbits.
    Gersl V, Hrdina R.
    Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove; 1994 Jan 21; 37(2):49-55. PubMed ID: 7784798
    [Abstract] [Full Text] [Related]

  • 7. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.
    Hequet O, Le QH, Moullet I, Pauli E, Salles G, Espinouse D, Dumontet C, Thieblemont C, Arnaud P, Antal D, Bouafia F, Coiffier B.
    J Clin Oncol; 2004 May 15; 22(10):1864-71. PubMed ID: 15143078
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Doxorubicin-induced cardiomyopathy: hemodynamic studies for evaluating the limit of therapeutic risk].
    Lenzhofer R, Magometschnigg D.
    Z Kardiol; 1983 May 15; 72(5):297-303. PubMed ID: 6880337
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Systolic time intervals and echocardiography in monitoring adriamycin-treated tumor patients].
    Schott G.
    Z Gesamte Inn Med; 1991 Jun 15; 46(8):280-2. PubMed ID: 1897287
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adriamycin-induced myocardial toxicity: new solutions for an old problem?
    Outomuro D, Grana DR, Azzato F, Milei J.
    Int J Cardiol; 2007 Apr 12; 117(1):6-15. PubMed ID: 16863672
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.